---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-26-000104"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-10-01T21:25:33+00:00"
generated_at: "2026-10-12T14:28:56.658717+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axogen closes BioCircuit acquisition, adding FDA-cleared NerveTape; sees ~$34M 2027 revenue contribution

## Summary
- Axogen completed its acquisition of privately held BioCircuit Technologies, Inc. on October 1, 2026, adding NerveTape, described as the first FDA-cleared device for sutureless peripheral nerve repair.
- BioCircuit expected to contribute approximately $6 million to Q4 2026 revenue and approximately $34 million to 2027 revenue.
- That contribution was not included in Axogen's most recently issued full-year 2026 guidance of at least 24% revenue growth.
- Company continues to expect full-year 2026 gross margin of at least 73% and to be free cash flow positive.
- CEO Michael Dale said NerveTape is 'simpler, faster, and more effective than microsuturing' and fits Axogen's direct sales and hospital contracting; purchase price not disclosed.

## SEC filing metadata
- accession: 0000805928-26-000104
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-10-01T21:25:33+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592826000104/0000805928-26-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592826000104/axgn-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-26-000104
- JSON: https://secwatch.observer/filing/0000805928-26-000104.json
- Plain text: https://secwatch.observer/filing/0000805928-26-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.